Work

Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy

Year: 2015

Type: article

Abstract: BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma. Clin Cancer Res; 21(14); 3102–4. ©2015 AACR. See related article by Kakavand et al., p. 3140

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-15-0363

Authors: Zachary A. Cooper, Alexandre Reuben, Jacob Austin-Breneman, Jennifer A. Wargo

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute